Skip to content

UroGen Pharma URGN Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$23.57M+10.6%-$26.36M+20.9%-$33.35M+33.2%-$49.94M-13.9%-$43.84M-16.9%
$75K0.0%$75K-25.0%$100K0.0%$100K+38.9%$72K+5.9%
$4.63M+47.8%$3.13M+3.4%$3.03M+10.8%$2.73M-10.9%$3.07M-7.1%
-$45.32M-18.2%-$38.33M+9.3%-$42.27M-6.1%-$39.83M+5.2%-$42.02M-209%
$54K+218%$17K-80.5%$87K-38.3%$141K+220%$44K-61.7%
-$20.69M-175%$27.72M-11.7%$31.4M+10.5%$28.41M+209%-$25.96M
$65.35M$0$0-100%
$65.2M+108%$31.32M+279%$8.27M+2,695%$296K+771%$34K-52.1%
-$800K-$2.6M+76.6%-$11.12M+83.6%-$67.95M-244%
-$45.37M-18.3%-$38.34M+9.5%-$42.36M-6.0%-$39.97M+5.0%-$42.07M-206%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does UroGen Pharma's cash flow data come from?
Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.